Posted: 8 December 2025
Evinco Therapeutics Pty Ltd has been officially launched in Melbourne as a new biotechnology company dedicated to transforming treatments for Alzheimer’s disease and other neuroinflammatory conditions. Based in Melbourne and led by CEO and Executive Chair Professor Alan Trounson AO, the company is established as a spin-out from Cartherics Pty Ltd, enabling Cartherics to focus on its cancer and endometriosis development programmes.
A direct quote appears early in the announcement. Prof. Trounson states: “Serendipity has opened the incredible potential benefit of autologous NK cell therapy for Alzheimer’s disease. We have shown that minuscule EVs extracted from NK cells have extraordinary effects on microglia… I am excited that this and other neuroprotective properties of NK-EVs may herald a new frontier in the fight against Alzheimer’s disease and other neuroinflammatory diseases.”
Evinco is raising capital to support proof-of-concept studies, with its research directed toward the use of Extracellular Vesicles (EVs) from Natural Killer (NK) cells as a novel therapeutic strategy for Alzheimer’s disease and other neurological conditions. These NK-EVs are designed for intranasal delivery, offering a simple method for transporting therapeutics directly into affected areas of the brain.
Alzheimer’s disease is the most common cause of dementia, now the leading cause of death in Australia. The global Alzheimer’s disease therapeutics market is forecast to reach USD $17 billion by 2033 across major markets, driven by an ageing population.
Supported by a skilled scientific team, experienced leaders and collaborators from leading academic and medical institutions, Evinco Therapeutics is positioned to accelerate the translation of research breakthroughs into real-world therapies. The company’s mission focuses on advancing new treatment opportunities in response to rising dementia rates, setting new benchmarks for innovation and patient outcomes in neurodegenerative disease.
